Moreover, given the recent breakthroughs in obesity treatment with GLP-1 receptor antagonists, these conditions (obesity and its downstream effectors) are becoming easier and more feasible to treat. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.